Surveillance of Multidrug-Resistant Pathogens in Neonatal Intensive Care Units of Palermo, Italy, during SARS-CoV-2 Pandemic.
NICU
SARS-CoV-2 pandemic
antimicrobial resistance
bacterial carriage
epidemiological trends
multi-drug-resistant pathogens
surveillance system
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
19 Sep 2023
19 Sep 2023
Historique:
received:
04
08
2023
revised:
12
09
2023
accepted:
14
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Antimicrobial resistance (AMR) is a topic of concern, especially in high-level care departments like neonatal intensive care units (NICUs). The systematic use of an "active" epidemiological surveillance system allows us to observe and analyze any changes in microbial distribution, limiting the risk of healthcare-associated infection (HAI) development. We have conducted a longitudinal observational study in the five NICUs of Palermo, comparing the "pre-pandemic period" (March 2014-February 2020) with the "pandemic" one (March 2020-February 2022). The primary aim of the study was to evaluate the cumulative prevalence of carriage from multi-drug resistant (MDR) bacteria in the cumulative NICUs (NICU C). During the "pre-pandemic period", 9407 swabs were collected (4707 rectal, 4700 nasal); on the contrary, during the "pandemic period", a total of 2687 swabs were collected (1345 rectal, 1342 nasal). A statistically significant decrease in MDR-Gram-negative bacteria (GNB) carriage prevalence was detected during the pandemic. At the same time, there was a general worsening of the carriage of carbapenemase-forming MDR-GNB (CARBA-R+) and methicillin-resistant The surveillance of MDRO carriage in NICUs is fundamental for limiting the social and economic burden of HAIs.
Sections du résumé
BACKGROUND
BACKGROUND
Antimicrobial resistance (AMR) is a topic of concern, especially in high-level care departments like neonatal intensive care units (NICUs). The systematic use of an "active" epidemiological surveillance system allows us to observe and analyze any changes in microbial distribution, limiting the risk of healthcare-associated infection (HAI) development.
METHODS
METHODS
We have conducted a longitudinal observational study in the five NICUs of Palermo, comparing the "pre-pandemic period" (March 2014-February 2020) with the "pandemic" one (March 2020-February 2022). The primary aim of the study was to evaluate the cumulative prevalence of carriage from multi-drug resistant (MDR) bacteria in the cumulative NICUs (NICU C).
RESULTS
RESULTS
During the "pre-pandemic period", 9407 swabs were collected (4707 rectal, 4700 nasal); on the contrary, during the "pandemic period", a total of 2687 swabs were collected (1345 rectal, 1342 nasal). A statistically significant decrease in MDR-Gram-negative bacteria (GNB) carriage prevalence was detected during the pandemic. At the same time, there was a general worsening of the carriage of carbapenemase-forming MDR-GNB (CARBA-R+) and methicillin-resistant
CONCLUSIONS
CONCLUSIONS
The surveillance of MDRO carriage in NICUs is fundamental for limiting the social and economic burden of HAIs.
Identifiants
pubmed: 37760753
pii: antibiotics12091457
doi: 10.3390/antibiotics12091457
pmc: PMC10525448
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : national funding
ID : CCM 2014 CUP G72C15000000001
Organisme : regional funding
ID : PSN 2014
Références
Antimicrob Resist Infect Control. 2022 Jan 21;11(1):12
pubmed: 35063032
Antimicrob Resist Infect Control. 2021 Oct 19;10(1):148
pubmed: 34666836
BMC Infect Dis. 2017 Mar 29;17(1):237
pubmed: 28356079
Lancet Infect Dis. 2019 Jan;19(1):56-66
pubmed: 30409683
Clin Microbiol Infect. 2014 Apr;20(4):O255-66
pubmed: 24131428
J Matern Fetal Neonatal Med. 2011 Oct;24 Suppl 1:23-6
pubmed: 21942585
J Med Microbiol. 2011 Nov;60(Pt 11):1651-1660
pubmed: 21719575
Microorganisms. 2021 Dec 17;9(12):
pubmed: 34946217
Front Public Health. 2020 Nov 04;8:535668
pubmed: 33251170
Medicine (Baltimore). 2016 Mar;95(10):e3016
pubmed: 26962817
Clin Infect Dis. 2015 May 1;60(9):1389-97
pubmed: 25595742
J Infect Public Health. 2023 Mar;16(3):320-331
pubmed: 36657243
Front Microbiol. 2023 Feb 20;14:1096223
pubmed: 36891399
Clin Microbiol Infect. 2021 Apr;27(4):520-531
pubmed: 33418017
Infect Control Hosp Epidemiol. 2022 Apr;43(4):461-466
pubmed: 33858547
J Antimicrob Chemother. 2021 Oct 11;76(11):3045-3058
pubmed: 34473285
Neoreviews. 2019 Mar;20(3):e135-e144
pubmed: 31261051
Microb Drug Resist. 2018 Oct;24(8):1128-1136
pubmed: 29368992
Clin Microbiol Infect. 2014 Jan;20 Suppl 1:1-55
pubmed: 24329732
Sisli Etfal Hastan Tip Bul. 2019 Mar 25;53(1):70-75
pubmed: 33536830
Reprod Health. 2014 Dec 17;11:89
pubmed: 25518862
Pediatr Infect Dis J. 2002 Nov;21(11):1029-33
pubmed: 12442024
Saudi Med J. 2015 Sep;36(9):1084-90
pubmed: 26318466
Pediatrics. 2023 Feb 1;151(2):
pubmed: 36625072
J Clin Med. 2023 Mar 30;12(7):
pubmed: 37048704
Antimicrob Resist Infect Control. 2021 Feb 4;10(1):30
pubmed: 33541419
Lancet Infect Dis. 2005 Aug;5(8):481-93
pubmed: 16048717
Lancet. 2015 Jan 31;385(9966):430-40
pubmed: 25280870
Antibiotics (Basel). 2022 Jun 20;11(6):
pubmed: 35740232
Clin Microbiol Infect. 2017 Dec;23(12):961-967
pubmed: 28412380
Pediatr Infect Dis J. 2022 Jun 1;41(6):482-489
pubmed: 35195565
BMC Res Notes. 2017 Jul 11;10(1):265
pubmed: 28693597
Antiinflamm Antiallergy Agents Med Chem. 2009 Sep;8(3):248-259
pubmed: 20498729
Lancet. 2017 Oct 14;390(10104):1770-1780
pubmed: 28434651
Antibiotics (Basel). 2022 Jul 09;11(7):
pubmed: 35884179
Antibiotics (Basel). 2022 May 20;11(5):
pubmed: 35625339
Infect Control Hosp Epidemiol. 2016 Nov;37(11):1302-1309
pubmed: 27511591
Clin Perinatol. 2021 Jun;48(2):379-391
pubmed: 34030820
Environ Res. 2020 Dec;191:110231
pubmed: 32976823
JAC Antimicrob Resist. 2022 Dec 29;5(1):dlac130
pubmed: 36601548
Clin Infect Dis. 2022 May 30;74(10):1748-1754
pubmed: 34370014
J Clin Microbiol. 1997 Sep;35(9):2432-3
pubmed: 9276435